e-ISSN: Pending

Browse the failure-mode index

12,251 real negative results, null findings, and replication failures in Medicine. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Negative / Null Result ReportMedicine

Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.

Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology

Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

View details →
Negative / Null Result ReportMedicine

Early worsening of diabetic retinopathy after simultaneous pancreas and kidney transplantation-Myth or reality?

Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…

View details →
Negative / Null Result ReportOpen accessMedicine

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology

Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…

View details →
Failed Experiment ReportMedicine

Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.

Jacobsen LM, Schatz D · 2025 · Hormone research in paediatrics

Background Type 1 diabetes (T1D) is more than an insulin-deficiency disease - it is an autoimmune disease, and the field is moving toward adopting disease-modifying immunotherapy as part of clinical care during T1D development. Summary…

View details →
Negative / Null Result ReportMedicine

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology

Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…

View details →
Negative / Null Result ReportMedicine

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.

O'Hara MH, Jegede O, Dickson MA et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…

View details →
Failed Experiment ReportOpen accessMedicine

Antibiotic treatment of bacterial lung infections in cystic fibrosis.

Taccetti G, Terlizzi V, Campana S et al. · 2024 · European journal of pediatrics

Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections are frequently observed. The aim of…

View details →
Failed Experiment ReportOpen accessMedicine

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.

Mosca M, Arnaud L, Askanase A et al. · 2025 · Lupus science & medicine

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in…

View details →
Negative / Null Result ReportMedicine

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

Bateman RJ, Li Y, McDade EM et al. · 2025 · The Lancet. Neurology

Background Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The…

View details →
Negative / Null Result ReportOpen accessMedicine

Medium-term oncological outcomes of totally laparoscopic colectomy with intracorporeal anastomosis for right-sided and left-sided colon cancer: propensity score matching analysis.

Hamamoto H, Suzuki Y, Takano Y et al. · 2022 · BMC surgery

Background This retrospective study aimed to compare long-term oncological outcomes between laparoscopic-assisted colectomy (LAC) with extracorporeal anastomosis (EA) and totally laparoscopic colectomy (TLC) with intracorporeal anastomosis…

View details →
Negative / Null Result ReportOpen accessMedicine

The role of hemostatic markers as venous stenosis or occlusion predictors following first transvenous cardiac device implantation.

Cacko A, Kozyra-Pydyś E, Gawałko M et al. · 2021 · Cardiology journal

Background Among patients with an implanted cardiac implantable electronic device (CIED), ipsilateral upper extremity vein stenosis or occlusion (VSO) is observed more frequently than in the general population. However, there are no data…

View details →
Negative / Null Result ReportMedicine

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.

Choueiri TK, Albiges L, Barthélémy P et al. · 2024 · Lancet (London, England)

Background Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing…

View details →
Negative / Null Result ReportOpen accessMedicine

Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.

Konno Y, Mayama M, Takehara K et al. · 2025 · Journal of gynecologic oncology

Objective This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence. Methods Japanese…

View details →
Failed Experiment ReportMedicine

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).

Pettengell R, Długosz-Danecka M, Andorsky D et al. · 2020 · British journal of haematology

PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not…

View details →
Failed Experiment ReportMedicine

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Tolaney SM, Sahebjam S, Le Rhun E et al. · 2020 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR + ) metastatic breast…

View details →
Negative / Null Result ReportMedicine

Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.

Rascol O, Tönges L, deVries T et al. · 2022 · Parkinsonism & related disorders

Background Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core…

View details →
Negative / Null Result ReportMedicine

EXPRESS: Lack of Association Between Inner Ear FLAIR Suppression on MRI and Laterality of Clinical Signs in Feline Idiopathic Vestibular Syndrome.

Putzer M, De Decker S, Gutierrez Quintana R et al. · 2026 · Journal of feline medicine and surgery

ObjectivesThe underlying aetiology of feline idiopathic vestibular syndrome (IVS) remains unclear. In humans, specific magnetic resonance imaging (MRI) sequences are used to demonstrate differences in endolymph composition between…

View details →
Negative / Null Result ReportMedicine

Lack of association between donor left ventricular hypertrophy and graft survival in the contemporary era of heart transplantation.

Mahar JH, Wayda B, Weng Y et al. · 2026 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Donor heart left ventricular hypertrophy (LVH) is a common reason for organ discard in the United States, despite limited contemporary data on its impact on transplant outcomes. Using Scientific Registry of Transplant Recipients data…

View details →